Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069994 | 1.00 | MEN1 (0.46) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL21069229 | 1.00 | MEN1 (0.46) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL17555598 | 0.98 | TSHR (0.43) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL22631509 | 0.86 | TSHR (0.45) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL28849721 | 0.83 | BLM (0.42) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL21070273 | 0.82 | BLM (0.41) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL21071250 | 0.82 | BLM (0.41) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL931842 | 0.82 | BLM (0.41) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL21001064 | 0.80 | KDM4E (0.37) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL25363263 | 0.79 | BLM (0.38) | MEN1KMT2ABLMPMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4114830-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Genentech, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885BLM 1454/4885 |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | MEN1 3483/4885KMT2A 2032/4885BLM 2625/4885 |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | MEN1 2876/4885KMT2A 2290/4885BLM 976/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | MEN1 3483/4885KMT2A 2032/4885BLM 2625/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885BLM 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.